

WORLD JOURNAL OF PHARMACEUTICAL RESEARCH

SJIF Impact Factor 8.084

Volume 9, Issue 8, 1295-1304.

Research Article

ISSN 2277-7105

A COMPARATIVE CLINICAL STUDY TO EVALUATE THE ADDED EFFICACY OF SHUNTHYADI GHRITHA AND AJAMODA NIRGUNDYADI YOGA IN THE MANAGEMENT OF AMAVATA VIS-ÀVIS RHEUMATOID ARTHRITIS

Pooja S.¹*, Sanjay Kumar M. D.² and V. Rajendra³

- ¹PG Scholar, Department of PG Studies in Kayachikithsa, Government Ayurveda Medical College, Mysuru.
- ²Assistant Professor, Department of PG Studies in Kayachikithsa, Government Ayurveda Medical College, Mysuru.
- ³Professor and Head, Department of PG Studies in Kayachikithsa, Government Ayurveda Medical College, Mysuru.

Article Received on 04 June 2020.

Revised on 25 June 2020, Accepted on 15 July 2020,

DOI: 10.20959/wjpr20208-17726

*Corresponding Author Dr. Pooja S.

PG Scholar, Department of PG Studies in Kayachikithsa, Government Ayurveda Medical College, Mysuru.

ABSTRACT

Introduction: Amavata is a vata-kapha pradhana tridoshaja vyadhi and rasavaha strotojanya vikara which is originating due to ama. It is mainly characterized by shoola(pain), shotha(swelling), and sthabhdata (morning stiffness) in sandhi due to vikruta vata associated with ama. The disease amavata has similarity with Rheumatoid arthritis in clinical presentation. Methodology: To compare and evaluate the added efficacy of Shuntyadi ghrita and Ajamoda nirgundyadi yoga (an indigenous formulation) in the management of Amavata vis-a-vis Rheumatoid Arthritis. It was a comparative clinical study with pre and post-test design, with sample size of 60 subjects, 30 subjects in each group. Assessment parameters used in the present

study were *sandhishoola*, *sandhi shotha*, *sandhi sthabhdata* and functional gradings. The data was collected on 0th day, 9th day (after *bastikarma*) and 30th day (after *shamanoushadhi*). **Result**: The overall assessment revealed that both the groups are equally effective. The comparision of results between the group is statistically insignificant, hence the hypothesis of difference in added efficacy between the group is disproved. **Conclusion:** In the present study, on comparing the overall effect, it was observed that both the groups are equally effective. Hence, *Dwipanchamooladi basti* followed by oral administration of *Shuntyadi*

ghrita and Dwipanchamooladi basti followed by oral administration of Ajamoda nirgundyadi yoga has a better role to play in the management of Amavata.

KEYWORDS: Amavata, Rheumatoid Arthritis, Shuntyadi ghrita, Ajamoda nirgundyadi yoga.

INTRODUCTION

Amavata is a pain predominating and movement restricting disease, it hampers the normal activities of the patient. Amavata poses a challenge to the physician owing to its chronicity, incurability, complications and morbidity. Amavata is a rasadushita vikara and is mainly due to the impairment of jataragni and dhatwagni, resulting in the production of ama. Such ama when gets associated with vikruta vata and gets located in sandhi produces shoola(pain), shotha(swelling) and Sthabhdata (stiffness) of sandhi (joints).^[1]

Amavata is having similarities with disease Rheumatoid arthritis.

Rheumatoid arthritis (RA) is a chronic systemic inflammatory polyarthritis that primarily affects small diarthrodial joints of the hands and feet in a symmetrical pattern. It is a heterogenous disease with variable severity, unpredictable course and a variable response to drug treatment.^[2]

Ayurveda explains two important treatment modalities i.e Shodhana and Shamana in the management of Amavata.

The line of treatment described in *Chakradatta*^[4] is as follows: *Agnideepana*, *Amapachana* and *Shodhana*. In the present study, *Dwipanchamooladi niruha basti*^[3] was administered to both the groups. It possess *amadoshahara*, *vata-kaphahara*, *rasayana*, *balya*, *vedanasthapaka*, *shothahara* properties.

OBJECTIVE

Primary objective

■ To evaluate and compare the added efficacy of *Shuntyadi ghrita* and *Ajamoda nirgundyadi yoga* in the management of *Amavata* vis-à-vis Rheumatoid Arthritis.

Secondary Objective

- ► To evaluate the combined effect of *Dwipanchamooladi niruha basti* followed by *Shuntyadi ghrita* in the management of *Amavata* vis-à-vis Rheumatoid Arthritis.
- To evaluate the combined effect of *Dwipanchamooladi niruha basti* followed by *Ajamoda nirgundyadi yoga* in the management of *Amavata* vis-à-vis Rheumatoid Arthritis.

MATERIALS AND METHODS

Source of Data: Subjects were selected from OPD and IPD of Government Ayurvedic Medical College and Hospital, Hi-Tech panchakarma Hospital, Mysuru.

Sample size and Sampling methods

- The study was completed in 60 patients, irrespective of gender, socio-economic status and religion, having the signs and symptoms of *Amavata* vis-à-vis Rheumatoid Arthritis were registered for the study with the help of a proforma prepared for the purpose of study after taking informed consent.
- Incidental selection and purposive sampling technique was employed.
- Out of 67 subjects registered, total number of droup outs are 7, 3 dropouts in Group A and 4 dropouts in Group B and the study was completed in 60 subjects with 30 subjects in each Group.

DIAGNOSTIC CRITERIA

■ The diagnosis was done based on the classical signs and symptoms of *Amavata* such as *ruja*(pain), *shotha*(swelling) and *sthambha*(morning stiffness) in the *sandhi*(multiple joints).

The new 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis

- Target population (Who should be tested?): Subjects who: Have at least 1 joint with definite clinical synovitis (swelling) With the synovitis not better explained by another disease.
- Classification criteria for RA (score-based algorithm: add score of categories A–D; A Score of >6/10 is needed for classification of a subject as having definite RA)

INCLUSION CRITERIA

■ Subjects irrespective of gender, aged between 18-60 years were included in the study.

- Subjects fit for *Basti karma* were included in the study.
- Both fresh cases and who have underwent treatment were included in the study.
- Individuals fulfilling the 2010 ACR EULAR classification criteria of Rheumatoid arthritis were included in the study irrespective of sero-positive or sero-negative Rheumatoid Factor.

EXCLUSION CRITERIA

- Subjects with co-morbidity of uncontrolled diabetes mellitus, uncontrolled hypertension and other systemic disorders which interferes with the intervention were excluded from the study.
- If subjects suffer with any rectal pathologies like heamorrhoids, fissure, rectal prolapse were excluded from the study.
- Pregnant & Lactating women were excluded from the study.

INTERVENTION

■ This was a comparative clinical trial consisting of two groups. The interventions were as follows.

Group A

■ Dwipanchamooladi niruha basti was administered in yogabasti pattern for first 8 consecutive days of interevention. Shuntyadi ghrita was administered orally in the dose of 12 ml once daily in the early morning before food, followed by luke warm water from 9th to 30th day.

Group B

■ Dwipanchamooladi niruha basti was administered in yogabasti pattern for first 8 consecutive days of interevention. Ajamoda nirgundyadi yoga was administered orally in the dose of 12gms in two equally divided doses twice daily after food with luke warm water from 9th to 30th day.

Period of Intervention is 30 days.

ASSESSMENT

In this study, total three assessments of the subjects were done. Pre-test assessment was done on 0th day, Mid assessment was done on 9th day(after *basti* therapy) and Post-test assessment i.e, after the completion of the intervention was done on 30th day.

STATISTICAL METHODS

The results were statistically analysed using statistical methods such as Descriptive statistics, Chi-square test, paired sample 't' test and Contingency co-efficient analysis.

INVESTIGATIONS

- ► For Assessment and Diagnostic purpose, following investigations were done before and after the completion of intervention:
- Rheumatoid Factor.
- C-reactive protein.
- ESR.
- Other blood investigations and urine analysis were done wherever necessary to exclude other systemic disorders.

OBSERVATIONS AND RESULTS

OBSERVATIONS

■ In the present clinical study, total 67 subjects were registered. Among them 33 subjects were assigned into Group A and 34 subjects were assigned into Group B. There were totally 7 droup outs, 3 drop outs in Group A and 4 drop outs in Group B at the various stages of intervention. Clinical study was completed in 60 subjects with 30 subjects in each group.

OVERALL ASSESSMENT

- In the present study, in Group A, maximum number of subjects i.e 14(47%) got moderate improvement, 12(40%) subjects got marked improvement and 4(13%) subjects got mild improvement.
- In Group B, maximum number of subjects i.e 17(57%) subjects got moderate improvement, 10(33%) subjects got marked improvement, and 3(10%) subjects got mild improvement.
- Overall assessment out of 60 subjects it is revealed that maximum number of subjects i.e 31(52%) subjects got moderate improvement, 22(37%) subjects got marked improvement, and 7(11%) subjects got mild improvement.
- The overall assessment revealed that both the groups are equally effective P value 0.004. The comparision of results between the group is statistically insignificant, hence the hypothesis of difference in added efficacy between the group is disproved.

Table no 1: showing the incidence of RA factor in subjects of Amavata.

Croun		RA F	Total	
Group		Positive	Negative	Total
	BT	25(83.0%)	5(17.0%)	30(100%)
Group A	AT	22(73.0%)	8(27.0%)	30(100%)
	Total	47(78.0%)	13(22.0%)	60(100%)
	BT	23(77.0%)	7(23.0%)	30(100%)
Group B	AT	21(70.0%)	9(30%)	30(100%)
	Total	44(73.0%)	16(27.0%)	60(100%)

Table no 2: showing incidence of C-Reactive Protein in RA subjects.

Crown		Cl	Total	
Group		Positive	Negative	Total
	BT	18(60.0%)	12(40.0%)	30(100%)
Group A	AT	13(43.0)	17(57.0%)	30(100%)
	Total	31(52.0%)	29(48.0%)	60(100%)
	BT	12(40.0%)	18(60.0%)	30(100%)
Group B	AT	10(33.0%)	20(67.0%)	30(100%)
	Total	22(37.0%)	38(63.0%)	60(100%)

Table no 3: showing the incidence of ESR in RA subjects.

ESR	GROUP A		GROUP B	
0-20mm/hr	BT	AT	BT	AT
U-2011111/111	3(10.0%)	12(40.0%)	2(7.0%)	10(33.0%)
21-40mm/hr	7(23.0%)	10(33.0%)	10(33.0%)	8(27.0%)
41-60mm/hr	5(17.0%)	6(20.0%)	6(20.0%)	5(17.0%)
61-80mm/hr	5(17.0%)	2(7.0%)	5(17.0%)	4(13.0%)
81-100mm/hr	7(23.0%)	0(0.0%)	6(20.0%)	3(10.0%)
>100mm/hr	3(10.0%)	0(0.0%)	1(3.0%)	0(0.0%)
Total	30(100%)	30(100%)	30(100%)	30(100%)

Table no 4: showing the results on reduction of Sandhishoola.

		Descriptive		Statistics	
	Sandhi shoola S1	Group	Mean	Standard Deviation	N
		Group A	26.6000	8.66506	30
S1	0 th day- Pre test	Group B	33.0800	10.76615	30
		Total	29.8400	10.21076	60
	9 th day – Mid test	Group A	8.9600	5.47327	30
S1		Group B	13.5200	7.28652	30
		Total	11.2400	6.78101	60
	30 th day – Post test	Group A	3.6800	3.70495	30
S1		Group B	9.8400	7.11618	30
		Total	6.7600	6.41923	60
Source	Type-III sum of	Df	Mean square	F	Significanc
	squares	Dι	ivicali squale	1,	e
Change	14978.613	2	7489.307	387.740	0.000

D		•		7
P	00	ıa	et	al.
_	· ·	•		~~

World Journal of Pharmaceutical Research

Change *group	26.453	2	13.227	0.685	0.507
Error(change)	1854.267	96	19.315		

Table no 5: showing the results on reduction of Sandhishotha.

		Descriptive	Statistics		
	Sandhi shotha S2	Group	Mean	Standard Deviation	N
		Group A	18.2000	6.50641	30
S2	0 th day- Pre test	Group B	19.0400	5.45802	30
		Total	18.6200	5.95867	60
		Group A	6.1600	4.20000	30
S2	9 th day – Mid test	Group B	8.3600	4.21189	30
		Total	7.2600	4.30856	60
		Group A	3.7600	7.51266	30
S2	30 th day – Post test	Group B	4.6000	3.95811	30
		Total	4.1800	5.95798	60

Source	Type-III sum of squares	df	Mean square	F	Significance
Change	5784.160	2	2892.080	164.567	0.116
Change *group	15.413	2	7.707	0.439	0.646
Error(change)	1687.093	96	17.574		

Table no 6: showing the results on reduction of Sandhisthabdata.

		Descriptive statistics			
	Sandhi sthabdata S3	Group	Mean	Standard Deviation	N
		Group A	23.3600	9.31790	30
S 3	0 th day- Pre test	Group B	27.4000	9.17424	30
		Total	25.3800	9.37624	60
		Group A	7.8800	5.51755	30
S 3	9 th day – Mid test	Group B	12.2000	6.46142	30
		Total	10.0400	6.33410	60
		Group A	3.2000	4.61880	30
S 3	30 th day – Post test	Group B	8.0000	6.35741	30
		Total	5.6000	6.01020	60

Source	Type-III sum of squares	df	Mean square	F	Significance
Change	10771.293	2	5385.647	325.510	0.000
Change *group	3.693	2	1.847	0.112	0.895
Error(change)	1588.347	96	16.545		

Groups Total 2 3 4 1 5 7 4 30 14 Group A Session Day 0 23.0% Grade 47.0% 13.0% 100% 19 30 Day 9 100% 23.0% 63.0% 7.0% 7.0% 22 1 30 6 1 Day 30 100% 20.0% 74.0% 3.0% 3.0% 34 39 10 90 Total 38.0% 43.0% 2.0% 8.0% 100% 10 14 0.0% 30 6 Group B Session Day 0 20.0% 33.0% 0.0% 100% 47.0% 0.0% 30 9 18 3 Day 9 30.0% 10.0% 60.0% 0.0% 100% 18 12 0 0.0% 30 Day 30 100% 60.0% 40.0% 0 0.0% 33 40 17 0.0% 90

Table no 7: showing the results on improvement of Functional Gradings.

37.0%

Tableno 8: showing the results on overall assessment.

Total

		Group		
		Cross tabulation		
		Group		Total
		A	В	10tai
Marked improvement	Count	12(40.0%)	10(33.0%)	22(37.0%)
Moderate	Count	14(47.0%)	17(57.0%)	31(52.0%)
improvement	Count	14(47.070)	17(37.0%)	31(32.070)
Mild improvement	Count	4(13.0%)	3(10.0%)	7(11.0%)
No improvement	Count	0(0.0%)	0(0.0%)	0(0.0%)
Total	Count	30(100%)	30(100%)	60(100%)

44.0%

19.0%

0.0%

100%

■ DISCUSSION

The ingredients of Dwipanchamooladi basti possess vata-kapha hara properties, vedanasthapaka, shothahara, deepana, pachana, balya, rasayana, jwarahara, anulomaka properties. Bruhat saindhavaadi taila^[5] used for Anuvasana basti possess vatanulomaka, shoolahara, shothahara along with Vata-kaphahara and tridoshahara properties. Hence it has therapeutic action in Amavata. Gomutra^[6] used for basti posseses tridoshahara, agnideepana, amapachana, sroto vishodana and vata anulomana properties, and also it is immnomodulatory in action and exhibits antioxidant properties.

Shuntyadi ghrita^[7] is Shoolahara, shophahara, jwarahara, adhmana hara, amavata hara, ojas tejo-balakaram, agnidipaka and aanaha hara in action. Gingerols and diaryl hepatanoids of

Shunti act as potent inhibitor of prostaglandin biosynthesis^[8] enzyme and acts as a potent GI stimulant. Hence, it is therapeutically effective in Amavata. Ghrita is ojas tejo-balakaram, agnidipaka, shula-jwara-aanaha hara. Shunti possesses Deepana and Pachana properties, which improve Jatharagni. When Jatharagni is improved, it leads to the formation of other Dhatus and checks the formation of Ama. By virtue of Ushna Veerya, it digests and absorbs the vitiated Ama by its Shoshana Karma. Scientifically, it has been proved that Shunti possesses active principles of gingerol, dehydrozingerone, and gingerdione, and they are potent inhibitors of prostaglandin synthesis, indicating the mechanism of an anti-arthritic effect. Hence, this formulation is effective in correcting the pathological condition of the disease Amavata.

Ajamoda nirgundyadi yoga^[9] contains drugs which are *tridoshahara*, mainly *vatakaphahara* with properties such as *amahara*, *deepaka*, *shoolahara*, *deepaka* and *balya* properties, ingredients also possess anti-inflammatory, analgesic and anti-rheumatic actions by this it is therapeutically effective in *Amavata*.

CONCLUSION

The disease *Amavata* explained in *Ayurvedic* classical texts is having close similarities in clinical presentation with the disease Rheumatoid Arthritis as explained in modern texts. The observation made in this study with respect to incidence of age and gender matches with general prevalence of Rheumatoid arthritis. In the present study, on comparing the overall effect of the study, it was observed that both the groups are equally effective. Hence, *Dwipanchamooladi basti* followed by oral administration of *Shuntyadi ghrita* and *Dwipanchamooladi basti* followed by oral administration of *Ajamoda nirgundyadi yoga* has a better role to play in the management of *Amavata*. Both groups showed statistically highly significant results. Hence, both are very effective in the management of RA. The comparision of results between the group is statistically insignificant, hence the hypothesis of difference in added efficacy between the group is disproved.

REFERENCES

- 1. Madhavakara:Madhava Nidana with Madhukosha Vyakhya, by Dr.Brahmanand Tripathi poorvardha, vol-1, Chaukhambha Surbharati prakashan, Varanasi, 2006; 25/8, pg no: 575.
- 2. API Textbook of medicine: Editor in chief –Yash pal Munjal, Vol-II, chapter- 24.3, By A N Malaviya, 9th edition, 2012; Chapter-24.6, pg no-1829.

- 3. Agnivesha: Charaka samhita, Charaka and Drdhabala, Edited with Charaka chandrika, hindi commentary, by Dr. Vidhyadhara shuklaand Dr Ravidatt Tripati, Chaukhamba Sanskrit prathishtan, Delhi, Vol II, 2007; edition, Siddhisthana, 3/59-60, Pg no-907-908.
- 4. Chakrapanidata:Chakradatta, Sri Indradeva Tripathi, chowkhambha Sanskrit series office, Varanasi, 2010; edition, Pg No 170.
- 5. Bhaishajyaratnavali of Shri Govind Das, edited and enlaged by Bhishagratna Shri Brahmashankar Mishra, Vidyotini hindi commentary analysis and appendixes by Shri Kaviraja Ambikadatta Shastri Ayurvedacharya, editor Shri Rajeshwara Datta Shastry, Chaukhambha Sansrit Sansthan, Varanasi.18th edition, 2005; 29/222-227, pg.no-630.
- 6. Research article-Global journal of pharmacology, 2008; 2(2): 20-22, Antioxidant and Antimicrobial activities of Cow urine, Mandsaur, Madhyapradesh, Pg.no-20-22.
- 7. Chakrapanidatta: Chakradatta, Dr. Indradeva Tripathi, Editor- Ramanath Dwivedy, Chaukambha Sanskrit Sansthan, Varanasi, 2010; P.no-169.
- 8. J L N Shastry, Text book of Dravyaguna Vignana, Chowkambha orientalia, Varanasi, edition 2010; vol 2: pg no. 521-524.
- 9. Bhavamishra:Bhava prakasha, Sri Bhavamishra with Vidyotini hindi commentary, editor Bhisagratna Pandit Sri Brahmasankar misra,Chaukhambha Sanskrit bhawan, Varanashi, 11th edition, 2007; vol I: pg no: 222,2,227.